# DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

Study · id `cardio:ct-nct07483801` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07483801](<https://clinicaltrials.gov/study/NCT07483801>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07483801

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 112 participants.

## Technical summary

Registry record NCT07483801. Randomized; double masking; primary purpose basic science. Start 2026-03 (anticipated); primary completion 2027-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose basic science
- Phase: Phase 4
- Enrolled: 112 participants (planned count; ClinicalTrials.gov record NCT07483801, source copy `cardio:ctgov-nct07483801-2026-03-19`, retrieved 2026-10-26)
- Planned start: 2026-03 (anticipated) (ClinicalTrials.gov record NCT07483801, source copy `cardio:ctgov-nct07483801-2026-03-19`, retrieved 2026-10-26)
- Primary completion: 2027-04 (anticipated) (ClinicalTrials.gov record NCT07483801, source copy `cardio:ctgov-nct07483801-2026-03-19`, retrieved 2026-10-26)
- Completion: 2028-04 (anticipated) (ClinicalTrials.gov record NCT07483801, source copy `cardio:ctgov-nct07483801-2026-03-19`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT07483801, source copy `cardio:ctgov-nct07483801-2026-03-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07483801-2026-03-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
- Acronym: DECODE
- Condition: Cardiovascular Diseases
- Intervention (Drug): semaglutide
- Intervention (Drug): Tirzepatide
- Lead sponsor: Cambridge University Hospitals NHS Foundation Trust
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Cambridge University Hospitals NHS Foundation Trust (`cardio:org-cambridge-university-hospitals-nhs-foundation-trust`)

## Provenance

Content hash: ca6f6720019346bcaefa3eb8f5458324b6c34d5cd68962048b6b3244fa6e0c56
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
